Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria
This article was originally published in PharmAsia News
TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code
You may also be interested in...
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls. Merck & Co., which aims to see one-fourth of its revenue come from emerging markets by 2013, focused investment in best growth drivers and sales efficiency to bolster key products. Merck's emerging markets strategy will focus on maximizing its own brands, leveraging partnerships with low-cost makers and looking for "inter-brand" opportunities.
Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference
SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation
GSK Diversification Pays Off With 21% Growth In Asia Pacific Sales: Emerging Markets Earnings Round Up (Part 1)
GlaxoSmithKline PLC April 27 released its first quarter results showing a handsome payoff for a diversification policy the pharmaceutical giant implemented three years ago. Although GSK overall sales declined 11%, strong growth in emerging markets and Japan helped offset losses from key products and bolster the net profit up by 14%.